Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EED | O75530 | 1/20 | 0.49 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.49 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.49 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523020 | 1.00 | HPGD (0.54) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL470530 | 1.00 | HPGD (0.54) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL12539193 | 0.94 | HPGD (0.56) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL25411425 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL31004147 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL30478265 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL359045 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL15657484 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL14241561 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL19560047 | 0.88 | HPGD (0.55) | HPGDGPR119RECQLEPHX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5017498-A | — | — | None | — | — | JP | disclosed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4540226-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-04-23 | — | — | EP | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| EP-3822262-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-1994022825-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0610192-A1 | ETHER DERIVATIVES OF ALKYL PIPERIDINES AND PYRROLIDINES AS ANTIPSYCHOTIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5317024-A | Administering to mammals | DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-05-31 | — | — | US | disclosed |
| WO-1994008962-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5272158-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5252586-A | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| WO-1993009094-A1 | ETHER DERIVATIVES OF ALKYL PIPERIDINES AND PYRROLIDINES AS ANTIPSYCHOTIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0540334-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| JP-H0517498-A | FIBRINOGEN RECEPTOR ANTAGONIST | MERCK & CO INC | 1993-01-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | HPGD 126/4885GPR119 610/4885RECQL 2689/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | HPGD 2822/4885GPR119 4295/4885RECQL 2281/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | HPGD 2266/4885GPR119 173/4885RECQL 3581/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | HPGD 126/4885GPR119 610/4885RECQL 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.